Business
CEL-SCI Corporation Announces Pricing of Public Offering
VIENNA, Va., May 12, 2026--CEL-SCI Corporation Announces Pricing of Public Offering.
About this update from Cel-sci Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/1f8d6b1d481fe5d6594bd244006cd147"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rtww2aBVqWO10cYNMmM6Pg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/1f8d6b1d481fe5d6594bd244006cd147","width":480,"height":240},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/nhMSagiFQbjyAI5xIi2WEg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTMyMA--/https://media.zenfs.com/en/business-wire.com/1f8d6b1d481fe5d6594bd244006cd147","width":480,"height":240}},"lazy":false},{"type":"text","content":"VIENNA, Va., May 12, 2026--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 6,000,000 shares of its common stock at an offering price of $1.20 per share. Total gross proceeds from the offering, before deducting the placement agent’s fees and offering expenses, are expected to be approximately $7.2 million. The offering is expected to close on May 13, 2026, subject to satisfaction of customary closing conditions.","length":586,"tagName":"p"},{"type":"text","content":"The Company intends to use the proceeds for the continued development of Multikine*, general corporate purposes, and working capital.","length":133,"tagName":"p"},{"type":"text","content":"ThinkEquity is acting as the sole placement agent for the offering.","length":67,"tagName":"p"},{"type":"text","content":"A registration statement on Form S-1 (File No. 333-295168) relating to the shares was filed with the Securities and Exchange Commission ("SEC") and became effective on May 11, 2026. This offering is being made only by means of a prospectus. Copies of the final prospectus, when available, may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. The final prospectus will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.","length":509,"tagName":"p"},{"type":"text","content":"This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of the...